CKS2: A Potential Drug Target and Biomarker for Cancer (G1164)

Target Name: CKS2

NCBI ID: G1164

CKS2

CKS2: A Potential Drug Target and Biomarker for Cancer

Cyclin-dependent kinases (CDKs) are a family of transcription factors that play a crucial role in cell proliferation and development. CDKs regulate the expression of genes by binding to specific DNA sequences, which allows them to control the timing and number of gene expressions. CDKs are involved in many cellular processes, including cell growth, differentiation, and checkpoint systems. The CDK inhibitor letrozole has been shown to be an effective treatment for various types of cancer, including breast and ovarian cancers. However, its mechanisms of action are not well understood.

One of the CDKs that has been well studied is CKS2, a key regulator of CDK activity. CKS2 is a 22-kDa protein that is expressed in various tissues and cell types, including stem cells, cancer cells, and egg cells. It is a key component of the G1-CDK complex, which is responsible for regulating CDK activity during the G1 phase of the cell cycle.

CKS2 plays a crucial role in regulating cell proliferation and apoptosis. It promotes the G1-CDK complex to activate CDK activity, which is necessary for cell growth and division. Additionally, CKS2 inhibits the activity of the CDK inhibitor p21, which is a negative regulator of CDK activity. This inhibition allows CDKs to accumulate and continue to promote cell growth.

CKS2 is also involved in the regulation of cell apoptosis. It has been shown to promote the expression of pro-apoptotic genes, such as Bax and p53, which are necessary for cell death. Additionally, CKS2 has been shown to inhibit the activity of the anti-apoptotic protein Bcl-2, which can prevent cell death.

CKS2 is a potential drug target for cancer because its activity can be inhibited by small molecules, such as Pectin. Petisin is a broad-spectrum CDK inhibitor that can inhibit the activity of CDK, thereby inhibiting the growth and spread of cancer cells.

In addition, CKS2 can also serve as a biomarker to detect the development of cancer. Some studies have shown that the expression level of CKS2 can reflect the aggressiveness and growth rate of tumors. Therefore, by detecting the expression level of CKS2, the severity of the tumor can be assessed and more accurate guidance for treatment can be provided.

CKS2 is also a potential biomarker for identifying cancer-specific subtypes. Some studies have shown that the expression of CKS2 is different in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that CKS2 may be a useful biomarker for identifying cancer subtypes and predicting the response to specific therapies.

In conclusion, CKS2 is a potential drug target and biomarker for cancer. Its activity in regulating cell proliferation and apoptosis makes it an attractive target for small molecules. Additionally, its potential as a biomarker for cancer subtypes makes it an important tool for the development of personalized therapies. Further research is needed to fully understand the mechanisms of CKS2 and its potential as a drug target and biomarker for cancer.

Protein Name: CDC28 Protein Kinase Regulatory Subunit 2

Functions: Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function

The "CKS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets